CDERs Advisors & Consultants Staff (ACS) Perspective on Preparing for Advisory Committee Meetings Igor Cerny, Pharm.D. Director, ACS CDER/FDA.
Center for Scientific Review National Institutes of Health Department of Health and Human Services Toni Scarpa NIH Peer Review: Continuity and Change APS/Cardiovascular.
FDA and Patient Interactions On Benefit-Risk Determinations
Update on New CSR Realignments Basic Oncology and Bioengineering
Considerations for an ADaM Submission
